Business Insider – 7:31AM PT| The United States Department of Health and Human Services has approved the sale of an antibiotic, called Sisyphe line, for the treatment of a rare parasitic infection that has been linked to an outbreak in the US.
The approval follows the approval of another drug, also named Sisymhe line.
It was approved in April by the US Food and Drug Administration.
The approval was announced Tuesday afternoon by Dr. Robert R. Shulkin, the secretary of health and human services.
The drug, a novel antibiotic called SISypheline, is the first drug approved by the FDA for the use of the antibiotic Sisomax in the United States, the agency said in a statement.
The agency did not say how much the drug will cost or when it will be available.
The FDA’s approval came after a public health response that began in April, when an outbreak of Sisophia bacteria in the San Francisco Bay Area infected at least 21 people.
The outbreak was linked to the use in the Bay Area of a contaminated syringe, which was then used in an outbreak at a New Jersey nursing home.
The drug was developed by a biotech company called Novartis.
Dr. Sholens said that Sisys has been available in the U.S. for at least 15 years, but the FDA approval of SISys marks a significant step toward getting the drug to patients.
Sisys is used to treat an infection called S. rubella.
It has a broad spectrum of side effects and can cause serious infections.
The U.K. health service also approved the drug for use in people who have been diagnosed with S. trachomatis.
The CDC is still looking into whether or not the drug should be used for people with other types of infection.
“This is a very important day for the U